280 related articles for article (PubMed ID: 31533907)
1. Changing the landscape for type 1 diabetes: the first step to prevention.
Dayan CM; Korah M; Tatovic D; Bundy BN; Herold KC
Lancet; 2019 Oct; 394(10205):1286-1296. PubMed ID: 31533907
[TBL] [Abstract][Full Text] [Related]
2. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.
Gaglia J; Kissler S
Biochemistry; 2019 Oct; 58(40):4107-4111. PubMed ID: 31523950
[TBL] [Abstract][Full Text] [Related]
4. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
Philips JC; Scheen AJ;
Rev Med Liege; 2002 Jun; 57(6):413-7. PubMed ID: 12180038
[TBL] [Abstract][Full Text] [Related]
6. Teplizumab: type 1 diabetes mellitus preventable?
Misra S; Shukla AK
Eur J Clin Pharmacol; 2023 May; 79(5):609-616. PubMed ID: 37004543
[TBL] [Abstract][Full Text] [Related]
7. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
[TBL] [Abstract][Full Text] [Related]
8. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
Simmons K; Michels AW
Rheum Dis Clin North Am; 2014 Nov; 40(4):797-811. PubMed ID: 25437293
[TBL] [Abstract][Full Text] [Related]
9. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
Vudattu NK; Herold KC
Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
[TBL] [Abstract][Full Text] [Related]
10. [Prevention strategies of type 1 diabetes: the focus in 2003].
Philips JC; Scheen AJ;
Rev Med Liege; 2003 Apr; 58(4):211-9. PubMed ID: 12868323
[TBL] [Abstract][Full Text] [Related]
11. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
12. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
Miller SA; St Onge E
Expert Opin Biol Ther; 2011 Nov; 11(11):1525-32. PubMed ID: 21913874
[TBL] [Abstract][Full Text] [Related]
13. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
Tooley JE; Vudattu N; Choi J; Cotsapas C; Devine L; Raddassi K; Ehlers MR; McNamara JG; Harris KM; Kanaparthi S; Phippard D; Herold KC
Eur J Immunol; 2016 Jan; 46(1):230-41. PubMed ID: 26518356
[TBL] [Abstract][Full Text] [Related]
14. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
Herold KC; Gitelman SE; Gottlieb PA; Knecht LA; Raymond R; Ramos EL
Diabetes Care; 2023 Oct; 46(10):1848-1856. PubMed ID: 37607392
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD3 mAbs for treatment of type 1 diabetes.
Kaufman A; Herold KC
Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
[TBL] [Abstract][Full Text] [Related]
16. Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
Felton JL
Immunohorizons; 2021 Jul; 5(7):535-542. PubMed ID: 34261674
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 clinical trials in type 1 diabetes mellitus.
Daifotis AG; Koenig S; Chatenoud L; Herold KC
Clin Immunol; 2013 Dec; 149(3):268-78. PubMed ID: 23726024
[TBL] [Abstract][Full Text] [Related]
18. Prevention of type 1 diabetes: where we are and where we are going.
Frontino G; Guercio Nuzio S; Scaramuzza A; D'Annunzio G; Toni S; Citriniti F; Bonfanti R
Minerva Pediatr (Torino); 2021 Dec; 73(6):486-503. PubMed ID: 34286946
[TBL] [Abstract][Full Text] [Related]
19. Prevention strategies for type 1 diabetes mellitus: current status and future directions.
Winter WE; Schatz D
BioDrugs; 2003; 17(1):39-64. PubMed ID: 12534319
[TBL] [Abstract][Full Text] [Related]
20. Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.
Thakkar S; Chopra A; Nagendra L; Kalra S; Bhattacharya S
touchREV Endocrinol; 2023 Nov; 19(2):22-30. PubMed ID: 38187075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]